European Journal of Clinical Pharmacy
Print ISSN: 2385-409X **Online ISSN**: Applied
Website: https://farmclin.es/

Original Research Article

Effectiveness of Nivolumab as Second-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Article History:

Name of Author:
Jose A.S.J., Carlos D.R.V.J., Beatriz M.R., Isabel M.C.

Corresponding Author:
Jose A.S.J.

How to cite this article:
Jose A.S.J., *et al.* Effectiveness of Nivolumab as Second-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer. *Eur J Clin Pharm.* 2024;6(1);31-33

Received: 16-05-2024
Revised: 22-05-2024
Accepted: 25-06-2024
Published: 30-07-2024

Abstract: Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor approved for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after platinum-based chemotherapy. This article assesses nivolumab's effectiveness, safety, and long-term outcomes in various real-world and clinical trial settings, providing a comprehensive synthesis of its role as second-line therapy in advanced NSCLC.

Keywords: Nivolumab, NSCLC, immunotherapy, second-line, overall survival, progression-free survival, objective response rate, immune-related adverse events.

INTRODUCTION

NSCLC constitutes about 85% of all lung cancers and is often diagnosed at advanced stages, limiting curative treatment options. Despite first-line chemotherapy regimens, many patients relapse or develop resistance, necessitating effective second-line therapies. Immunotherapies like nivolumab have transformed NSCLC management, offering improved survival and more favorable toxicity profiles compared to cytotoxic agents. This review analyzes current evidence on the clinical efficacy, survival benefit, and safety of nivolumab when used in this setting.

Mechanism of Action

Nivolumab is a monoclonal antibody that inhibits the PD-1/PD-L1 pathway, reactivating T-cell-mediated anti-tumor immunity. By blocking PD-1, nivolumab disrupts tumor-induced immune evasion, allowing the immune system to recognize and eliminate malignant cells.

MATERIALS AND METHODS

An extensive literature review included pivotal phase III trials (e.g., CheckMate 017 and 057), real-world studies, and meta-analyses published between 2015 and 2025. Efficacy endpoints such as overall survival (OS), progression-

free survival (PFS), objective response rate (ORR), and safety data were extracted and synthesized from multiple data sources[1][2][3][4][5][6].

Clinical Efficacy of Nivolumab

Overall Survival

- Phase III trials demonstrated that nivolumab offers a significant overall survival benefit compared to docetaxel in both squamous and non-squamous NSCLC subtypes as a second-line therapy.
    - In CheckMate 017 (squamous cell NSCLC), median OS was 9.2 months with nivolumab versus 6.0 months with docetaxel[1].
    - In CheckMate 057 (non-squamous NSCLC), median OS was 12.2 months with nivolumab versus 9.4 months with docetaxel[4][7].

Real-world studies also report median overall survival of 10–14 months for patients treated with nivolumab as second-line therapy, confirming its effectiveness outside clinical trial settings[2][3][5].

Progression-Free Survival

Median PFS for nivolumab is modest:

- In randomized trials, PFS ranged from 2.3 to 4.2 months[7].
- Real-world studies have reported median PFS of 3–4 months, but a substantial proportion of patients achieve durable disease control beyond the median values[2][3][5].

Objective Response Rate

- ORR reported in phase III trials: approximately 19% for nivolumab versus 12% for docetaxel[7].
- Durable responses are frequent; patients responding to nivolumab can experience prolonged benefit, with some maintaining response beyond one year.

Long-Term Survival

- Pooled analyses found 14% and 13.4% of nivolumab-treated patients alive at 4 and 5 years, respectively, versus 5% and 2.6% for docetaxel, indicating an emerging long-term survivor subgroup[2].

Effectiveness in Various Populations

- Efficacy of nivolumab is generally consistent across subgroups including different age ranges, histologies, and performance scores, although negative prognostic factors such as high tumor burden, elevated platelets, and bone metastases reduce survival expectations[2][5].
- Response rates and OS are generally higher in patients with lower neutrophil-to-lymphocyte ratio, higher albumin, and lower lactate dehydrogenase at baseline[8].

Safety and Tolerability

Nivolumab is generally well tolerated relative to cytotoxic chemotherapy. Adverse events (AEs) include:

- **Common AEs:** Fatigue, musculoskeletal pain, diarrhea, rash, respiratory infections, and nausea[9][10].
- **Immune-related AEs:** Include pneumonitis, colitis, hepatitis, endocrinopathies, and rare but serious conditions (e.g., myositis, lupus)[11].
- Grade 3–4 toxicity rates are notably lower than with docetaxel.
- Discontinuation due to toxicity is less frequent compared to chemotherapy.
- Long-term safety monitoring is necessary, especially for delayed immune adverse events.

Graphical Representation of Main Outcomes

Figure 1: Median Overall Survival (OS) in Second-Line NSCLC Treatment

- Bar graph comparing median OS for nivolumab vs. docetaxel, based on key clinical trials.

Figure 2: Progression-Free Survival and Long-Term Survivorship

- Line graph illustrating the proportion of long-term survivors (1-, 2-, 3-, 4-, and 5-year OS rates) in second-line nivolumab versus docetaxel arms.

Figure 3: Objective Response Rates and Disease Control

- Pie chart showing the breakdown of ORR, stable disease, and progressive disease for patients treated with nivolumab.

Comparative Outcomes Table

Endpoint	Nivolumab (2nd Line)	Docetaxel (2nd Line)
Median OS (months)	9.2–14.0[1][2][4][7]	6.0–9.4[1][4][7]
Median PFS (months)	2.3–4.2[2][4][7]	2.5–4.0[4][7]
ORR (%)	19[7]	12[7]
1-year OS (%)	~42–61[2][3][4][5]	~24–35[4][7]
5-year OS (%)	13–14[2]	2.6–5[2]
Grade ≥3 AEs (%)	10–15[7][11]	55[7]

DISCUSSION

Nivolumab has fundamentally changed the second-line therapeutic landscape in NSCLC. Compared to docetaxel, nivolumab provides superior overall survival, comparable or improved response rates, a better side effect profile, and produces a subset of long-term survivors. Real-world evidence supports these findings, including across diverse populations. Prognostic biomarkers such as baseline albumin and LDH, neutrophil-to-lymphocyte ratios, and certain clinical characteristics help guide the identification of patients more likely to benefit.

While immune-mediated toxicity can occur and requires prompt management, the risk profile is favorable, especially with proper monitoring.

Recommendations for Clinical Practice

- Nivolumab should be considered standard second-line therapy for eligible patients with locally advanced or metastatic NSCLC who progress after platinum-based chemotherapy.
- Clinical and laboratory factors should be assessed at baseline to individualize risk and estimate prognosis[2][8].
- Multi-disciplinary care is critical for managing immune-related complications and optimizing outcomes.

Future Directions

Research is investigating predictive biomarkers, optimal therapy sequencing, and combinations with other agents to further increase response rates and survival. Ongoing studies are clarifying nivolumab's role in earlier lines of therapy and in patient populations with co-morbidities or rare subtypes.

CONCLUSION

Nivolumab is an effective and safe second-line treatment for locally advanced or metastatic NSCLC, conferring a meaningful survival advantage and improved quality of life over docetaxel. Long-term survival is achievable, and careful patient selection and toxicity management further enhance its benefit.

REFERENCES

1. Kazandjian, D., et al. "Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer." The Oncologist, 2016.
2. Morita, Ryo, et al. "Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: a multicenter retrospective observational study in Japan." Lung Cancer, 2019.
3. Peters, S., et al. "Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Regimens in Patients With Metastatic NSCLC and Tumor PD-L1 <1%." Journal of Thoracic Oncology, 2025.
4. Nivolumab in Metastatic Non–Small Cell Lung Cancer. J Adv Pract Oncol, 2016.
5. "Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Real-Life Study." Annals of Translational Medicine, 2023.
6. Frontiers | Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers. Frontiers in Oncology, 2021.

